Allogeneic haematopoietic SCT (allo-HSCT) from a matched sibling donor is a curative treatment option for patients with high-risk ALL. Congenital or acquired diseases of the donor are potentially transmissible to the recipient.
/l and bleeding time 300 s; there were no recent bleeding signs present before donation. As the sister was the only suitable family donor and the potential complications from her donation were considered manageable, a mobilization procedure was planned, preceded by a 10-day treatment with prednisone (1 mg/kg/day). During this treatment, the donor's plt count increased gradually to 85 Â 10 9 /l. After 5 days of G-CSF (10 mg/kg/day), a single leukapheresis was performed at a plt count of 80 Â 10 9 /l. Altogether, 5.2 Â 10 6 CD34 þ cells per kg of the recipient's body weight were collected without any complications.
In March 2004, the patient underwent allo-HSCT with an unmanipulated graft following a conditioning regimen with TBI, CY and VP-16. His plt count before transplantation was normal (298 Â 10 9 /l). The patient's RBCs were type A, Rh-negative, and the donor's were type O, Rhnegative. Standard GVHD prophylaxis was given. The post transplant period was essentially unremarkable, with neutrophil engraftment by day þ 18 and plt recovery above 20 Â This is a report of haematopoietic stem cell donation from a person with ITP. [6] [7] [8] The possibility of acquiring an autoimmune disease after HSCT by the direct transfer of an existing donor's autoreactive cells (adoptive transfer) with the graft is well known and not unusual. 2, 9 However, HSCT from donors with severe forms of rheumatoid arthritis or systemic lupus erythematosus does not inevitably provoke an autoimmune disease in the recipient, underlining the role of the host in immune regulation and disease expression. 1 Autoimmune cytopenias following BMT reflect an inadequate post transplantation immunologic control caused by a possible selective dropout of critical T-suppressor clones. 5, 10 Immune dysfunction related to chronic GVHD is reported to be associated with autoimmune phenomena because of the development of Abs against tissue cellular Ags and blood cells. 3 In some reports, post transplantacquired autoimmune thrombocytopenia was attributed to a direct transfer of Ig-producing lymphocytes with the graft. 6, 7 In our case, the possible cause for the observed thrombocytopenia after HSCT was studied after excluding a BM underproduction. The plt counts remained low despite the high megakaryocyte number in the BM and during the whole GVHD-free interval until day þ 210. The attempt to identify simultaneously plt-specific Abs in the donor and the recipient confirmed the presence of Abs to the IIb/IIIa glycoprotein complex only in the recipient's blood sample. The existence of plt-specific Abs cannot confirm by itself the thesis of transferred autoimmunity as such Abs can be found in association with various immune-mediated conditions and GVHD after transplantation. 3, 10 Treatment with corticosteroids and immunosuppressive drugs for GVHD proved effective in raising plt counts. For these reasons, we suspect that the thrombocytopenia was caused by a transfer of plt-reactive lymphocytes/precursors with the graft.
In a similar case report, thrombocytopenia did not occur after successful HSCT from a donor with chronic ITP. 8 However, in this case, the graft was T-cell depleted.
According to this report and the reviewed literature, we conclude that, in the absence of an alternative choice, a donor with ITP may be considered appropriate for graft collection with almost no risk from the donation. The possible transmission of a donor's autoimmune disorder to the recipient is an acceptable and manageable risk, keeping in mind the benefits from successful treatment of the primary malignant disease. 
